Lipid-Lowering Agents.
Antibodies, Monoclonal
/ therapeutic use
Anticholesteremic Agents
/ therapeutic use
Benzimidazoles
/ therapeutic use
Caproates
/ therapeutic use
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Diacylglycerol O-Acyltransferase
/ antagonists & inhibitors
Dicarboxylic Acids
/ therapeutic use
Dyslipidemias
/ blood
Ezetimibe
/ therapeutic use
Fatty Acids
/ therapeutic use
Genetic Therapy
Humans
Hypertriglyceridemia
/ drug therapy
Hypolipidemic Agents
/ therapeutic use
Lipoprotein(a)
/ blood
Oligonucleotides
/ therapeutic use
RNA, Small Interfering
/ therapeutic use
atherosclerosis
dyslipidemias
humans
lipoprotein(a)
oligonucleotides, antisense
Journal
Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
16
11
2019
Statut:
ppublish
Résumé
Several new or emerging drugs for dyslipidemia owe their existence, in part, to human genetic evidence, such as observations in families with rare genetic disorders or in Mendelian randomization studies. Much effort has been directed to agents that reduce LDL (low-density lipoprotein) cholesterol, triglyceride, and Lp[a] (lipoprotein[a]), with some sustained programs on agents to raise HDL (high-density lipoprotein) cholesterol. Lomitapide, mipomersen, AAV8.TBG.hLDLR, inclisiran, bempedoic acid, and gemcabene primarily target LDL cholesterol. Alipogene tiparvovec, pradigastat, and volanesorsen primarily target elevated triglycerides, whereas evinacumab and IONIS-ANGPTL3-L
Identifiants
pubmed: 30702996
doi: 10.1161/CIRCRESAHA.118.313171
doi:
Substances chimiques
ALN-PCS
0
Antibodies, Monoclonal
0
Anticholesteremic Agents
0
BMS201038
0
Benzimidazoles
0
Caproates
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Dicarboxylic Acids
0
Fatty Acids
0
Hypolipidemic Agents
0
ISIS 304801
0
Lipoprotein(a)
0
Oligonucleotides
0
RNA, Small Interfering
0
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
1EJ6Z6Q368
mipomersen
9GJ8S4GU0M
gemcabene
B96UX1DDKS
Diacylglycerol O-Acyltransferase
EC 2.3.1.20
Ezetimibe
EOR26LQQ24
evinacumab
T8B2ORP1DW
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
386-404Subventions
Organisme : CIHR
Pays : Canada
Organisme : NHLBI NIH HHS
ID : P01 HL088093
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL055798
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL106579
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL078610
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL124174
Pays : United States
Commentaires et corrections
Type : ErratumIn